Forest Laboratories Licenses Novel NMDA Receptor Antagonist from Merz + Co.
Forest Laboratories, Inc. (NYSE: FRX) announced that it has entered into a license agreement for the development and marketing in the United States of neramexane, a patented novel NMDA receptor antagonist developed by Merz + Co. of Germany. Financial terms of the transaction were not disclosed. NDMA receptors mediate a number of neurological functions. In a program which has already commenced, neramexane will be investigated in Phase II studies for a broad range of possible indications. Merz is also the innovator of memantine, another NMDA receptor antagonist licensed to Forest, which is being developed for Alzheimer's disease and for neuropathic pain. Forest expects to file the NDA for the Alzheimer's indication for memantine this fiscal year. Forest's Chairman Howard Solomon stated: "We are pleased to expand our collaboration with Merz, a highly regarded company that has conducted extensive research in the area of NMDA receptors and their activity related to neurological and psychiatric illnesses. We look forward to continuing developments with Merz in this exciting area."
Topics
Organizations

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.